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EDITORIAL REVIEW
The cellular physiology of glandular kallikrein
The biology of kallikrein has been reviewed from various
vantage points over the past decade [1—41. The present review
focuses on renal kallikrein, but includes a survey of a number of
areas in which substantial advances have been made over the
past two to three years. Such areas include the elucidation of
genomic and cDNA sequences of kallikreins and related pep-
tides, refinements in methodology, and the identification and
localization of kallikrein in additional extra—renal tissues such
as prostate and pituitary.
Kallikreins belong to a family of serine protease enzymes
involved in proteolysis of peptides to yield biologically active
fragments. Glandular kallikreins, the subject of this review,
need to be distinguished from plasma kallikrein. Plasma kal-
likrein has a different molecular wt, a slightly different profile of
enzyme activity and a different function, that of a role in the
intrinsic coagulation pathway [51. In this review the unqualified
term kallikrein thus should be taken to refer to glandular
kallikrein.
Though many authors discuss 'kallikrein' as though it were a
single entity, such is not the case. For ease of reference,
however, the singular 'kallikrein' is often used to cover this
family of closely related enzymes. Kallikrein (EC 3.4.21.8), like
other serine proteases, is characterized by the presence of a
serine residue in the active catalytic site. The ability to specif-
ically cleave kallidin from kininogen distinguishes kallikrein
from other serine proteases. Unlike certain other serine
proteases, kallikrein has a limited substrate—cleavage speci-
ficity, with a general but not absolute preference for residues
with positive side—chains, and a strong bias for arginine over
lysine, as reviewed by Fiedler [61.
Kallikreins are glycoproteins, single polypeptide chains with
a molecular weight of 27,000 to 40,000 and an isoelectric point
close to pH 4 [3, 4, 6]. Though the enzyme activity of kallikrein
is similar to that of trypsin, its response to various inhibitors is
clearly different. The substrate for plasma (and probably glan-
dular) kallikrein is hepatic—derived kininogen, which circulates
both as low (Mr 50,000 in human plasma) and high (Mr 120,000)
molecular wt forms [7]. Both forms appear to be a substrate for
glandular kallikrein, but only the high molecular wt form is
cleaved by plasma kallikrein [2].
The sequence of the bovine kininogens has recently been
established by recombinant DNA techniques, in that both the
gene and the cDNA for high and low molecular wt kininogen
have been cloned [81. It appears that the two different mRNAs
and polypeptides are derived from a single gene by differential
processing of the primary transcript. This is not to say that
kininogen is the unique substrate for kallikrein; there may well
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be different local substrates in each of the tissues where
kallikrein is found. For instance, kallikrein can specifically
cleave the apolipoprotein B-l00 of human plasma low density
lipoproteins into two specific fragments [9], and in vitro,
kallikrein can cleave inactive renin to active renin [10, 11].
As shown in Figure 1, glandular kallikrein cleaves kininogen
to yield the kinin, kallidin (lys-bradykinin), whereas both tryp-
sin and plasma kallikrein produce bradykinin [2, 6]. An excep-
tion to this rule may be the rat in which glandular kallikrein has
been reported to cleave kininogen to produce bradykinin [12].
Kallidin is further processed to bradykinin by an aminopepti-
dase [13]. As befits putative local effectors, both kallidin and
bradykinin have very short half—lives, being rapidly inactivated
by various kininases, particularly angiotensin—converting en-
zyme or kininase II [14]. Bradykinin is known to be a potent
vasodilator, to increase chloride transport across plasma mem-
branes [15], and to activate phospholipase [16]. A reported
effect of lys.bradykinin is to stimulate the amiloride—sensitive
influx of sodium in cultured human fibroblasts, resulting in
increased DNA synthesis [17].
Molecular biology
The structural basis of the enzyme activity appears analogous
to that of trypsin, a related serine protease which has been
studied in considerably more detail. Serine proteases fall into
two well—defined homologous systems, the microbial proteases
on one hand, and those of the eukaryotes on the other [18]. The
amino acid sequence characteristic of the latter at their active
site is Gly-Asp-Ser-Gly. In addition, serine proteases all have a
histidine residue separated by over 100 residues from the
serine, but easily juxtaposed with the active site, suggesting a
common three—dimensional structure, a hypothesis strength-
ened by the presence of homologous disulphide bonds [18]. The
serine protease catalytic site commonly includes an aspartate
between the histidine and serine to form the active site triad [19,
20]. The other important functional domain is the specific
substrate binding pocket, interacting with hydrophobic residues
on the substrate and conferring specificity [20, 21]. As with
other proteolytic enzymes, serine proteases require cleavage of
a short amino—terminal pro-sequence for activation of the
zymogen (pro-enzyme); removal of this peptide is thought to be
accompanied by a conformational change necessary for enzy-
matic activity [22].
Characterization of the amino acid sequence of porcine
pancreatic kallikrein [23] enabled the subsequent identification
of cDNA clones for other glandular kallikreins, thus providing
their amino acid sequences. Richards and colleagues [24] iden-
tified a cDNA clone expressed in high abundance in a male
mouse submaxillary gland cDNA library. Nucleotide sequence
analysis showed a 65% homology with the porcine pancreatic
kallikrein sequence. Extensive homology, but not identity, was
found between the predicted amino acid sequence of this
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Kininogen Met-Lys-Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-Arg-Ser...
Glandular kallikrein
Lys-Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-ArgKallidin
(Lys-Bradykinin)
Bradykinin
Aminopeptidase
Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-Arg
Kininase II f Kininase I
(angiotensin converting
enzyme)
Fig. 1. Partial amino acid sequence of kininogen, and enzymatic steps
in generation and metabolism of bradykinin.
protein, and analogous sequences in the two partially charac-
terized mouse submaxillary gland enzymes (EGF-binding pro-
tein and 'y-renin). Similar extensive homology has recently also
been shown with the y—subunit of nerve growth factor (NGF),
as well as with the inactive y—subunit of NGF; this latter is
contiguous with y—NGF on the genome, and has an exon 2
mutation consistent with its retained binding but loss of enzy-
matic activity [22]. This closely related subgroup of serine
proteases is characterized by the ability to cleave synthetic
esters of arginine; they are consequently termed arginyl-
esteropeptidases [25]. While they are trypsin—like in their
activity and primary structure, commonly recognizing and
cleaving to basic amino acids, they have a much narrower range
of substrate specificity than trypsin.
Using the initial mouse kallikrein cDNA probe (pMK- I),
Mason et al [20] showed that there are 25 to 30 different
kallikrein genes in the mouse genome as defined by cross—
hybridization. They also showed that these are all located on
chromosome 7, suggesting that the members of this gene family
may be closely linked and which has been confirmed in subse-
quent studies [22]. To probe submaxillary gland RNA, various
genomic fragments were used which hybridized to a common
class of mRNA, size —950 nucleotides, underscoring the size
homogeneity of the various kallikreins expressed in this tissue
[20].
The complete structure of these three kallikrein genes, with
four introns and five exons, is shown in cartoon form in Figure
2. The mature message encodes a preprokallikrcin of 261 amino
acids, including a signal peptide of 18 amino acids and a 6 amino
acid zymogen peptide analogous to that seen for trypsin.
Minimal variations in genomic structure and processing pat-
terns are seen between the characterized kallikrein genes [22].
The active kallikrein comprises 237 amino acids and contains a
glycosylation site analogous to that seen in a- and y-NGF [20,
22]. Kallikreins characterized to date (plus a- and y-NGF, EGF
binding protein and y-renin) show 73 to 80% homology, with
variations in the residues which make up the substrate—binding
pocket allowing differing substrate specificity. In contrast, the
residues at the serine protease catalytic site are conserved [20,
22, 26].
The other species in which kallikrein has been cloned is the
rat. The clone (pc XP39) was derived from a rat pancreatic
cDNA library and identified by its 57% homology with the
porcine pancreatic sequence [19]. It also shows 99% homology
with the partial amino acid sequence of rat submaxillary kal-
likrein [19], and 71% with mouse submaxillary gland kallikrein
sequence [24]. Limited homology is also seen with the family of
serine proteases coordinately expressed in the pancreas; this
homology is more fully discussed in Pancreatic kallikrein. Swift
et al [19] also showed cross—hybridization on Northern blotting
with an mRNA species of 1.1 kilobases from rat submaxillary
gland, spleen, parotid and kidney, but not lung, liver, lacrimal
gland or intestine.
From the primary structure and the known properties of
other arginyl-esteropeptidases, the maturation steps appear to
involve cleavage of the signal peptide (amino acids —24 to —7)
after transport into the rough endoplasmic reticulum. After
secretion (or perhaps insertion into the plasma membrane), the
zymogen or pro-sequence (amino acids —6 to — 1) is removed,
by a trypsin—like cleavage, to yield the fully active kallikrein.
The tertiary structure of this and other kallikreins provides an
autolysis ioop, with cleavage between amino acids 87 and 88
and the removal of several more amino acids. The resulting
two—chain conformation has been observed for purified porcine
pancreatic kallikrein 123] and is still enzymatically active [19].
A further serine protease identified in the rat submaxillary
gland is tonin, which shows 71% homology with rat pancreatic
kallikrein, as well as a high degree of homology with the other
serine proteases [27]. Its substrate specificity differs from that
of the kallikreins, and includes the in vitro ability to cleave
specifically angiotensin II and pro-opiomelanocortin (POMC)
[28]. It has an amino acid substitution in the active site triad
(leucine for the aspartate), while the serine and histidine are
retained. Again, it shows an autolysis loop structure and a
glycosylation site.
Recently, the same workers [29] have partially sequenced an
androgen—dependent arginyl-esteropeptidase from canine pros-
tate. Its two chains show >50% homology with other members
of the kallikrein family, suggesting again that the two—chain
structure results from autolysis of a single chain initial pro-
enzyme transcript [29].
Renal knllikrein
Measurement and methodologies
While the majority of structural and enzymatic studies have
used the pancreas and/or submaxillary gland, most of the
known physiology of kallikrein relates to the kidney; this is
even more the case in terms of pathophysiology. Any review of
the extensive literature on renal kallikrein must therefore ex-
amine the numerous methods used to measure and define
"kallikrein".
Much early work involved enzyme—activity assays, based on
the ability of kallikrein to hydrolyse synthetic esters of arginine.
Several other enzymes, however, show similar activity [12, 30,
31]. More recently developed synthetic substrates have an
advantage over assays using kininogen as substrate in that they
avoid interference from plasma kallikrein; their relative non-
specificity, however, remains a problem [32].
Studies with kininogen as substrate and measurement, usu-
ally by specific radioimmunoassay, of the production of brady-
kinin have greater specificity [33, 34]. Neither method, how-
ever, detects inactive kallikrein; the complementary use of
enzymes such as trypsin, to yield "total kallikrein activity" in
vitro [35, 36], has several potential sources of error. Similarly,
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the ability of aprotinin (Trasylol®) to inhibit activity has been
used as an index of specificity, though aprotinin is a polyvalent
inhibitor and may inhibit other renal serine proteases [37, 38].
Antibodies to kallikrein have been developed which are specific
and see both active and inactive kallikrein. They do not,
however, bind membrane—bound kallikrein with the same af-
finity as solubilized kallikrein [29, 30, 39, 40].
Studies on renal kallikrein are made even more difficult by the
cellular heterogeneity of the tissue. Urinary kallikrein [39] has
been used as a measure of distal tubular kallikrein activity, an
assumption with clear limitations. Both increased glomerular
filtration rate and increased distal tubular flow can acutely
increase urinary kallikrein levels [41—43]. Urine also contains
other proteases [31, 44—46], pre-formed kinins [1] and protease
inhibitors [29, 47]. It has been suggested that urinary kinins
should be measured only in samples taken directly from the
ureter [481. Where this has been performed, with the parallel
measurement of pre-existing kinins, the dissociation between
the two measurements suggests that in many situations urinary
kallikrein does not adequately reflect alterations in the intrare-
nal kallikrein—kinin system [48]. Others have found a good
correlation in the chronic, stable situation between urinary
kallikrein excretion and renal kallikrein activity [49].
Various models have been used to simplify studies of this
complex organ, including the isolated perfused kidney [50],
isolated nephron segments [36] and the toad urinary bladder
[51], a tissue which exhibits many of the functional character-
istics of the mammalian renal distal tubule [52]. Unfortunately,
no satisfactory cell line exists at present to enable studies in cell
culture.
Localization
On the basis of stop flow studies in the dog kidney [53],
immunohistochemistry [54, 55], immunoelectron microscopy
[56] and direct radioimmunoassay of microdissected rat neph-
ron segments [57], renal kallikrein has been localized to the
luminal cells of the distal convoluted tubule between the
JG-apparatus and the cortical collecting tubule. In the rabbit
Fig. 2. Cartoon of the expression of the mouse kallikrein gene. The
top line shows the arrangement of the genome, with exons shown
boxed and introns as lines. The mature message, with introns
removed, is translated to yield preprokallikrein. Post-translational
processing involves cleavage of a signal peptide of 21 amino acids,
and removal of six amino acids from the resultant zymogen form to
produce active kallikrein (adapted from [20]).
isolated nephron model, aprotinin—inhibitable proteolytic activ-
ity [58], and both active and total (activity after trypsin treat-
ment) kininogenase activity [37], were localized in the granular
portions of the distal and cortical collecting tubules. On hybrid-
ization histochemistry with the mouse kallikrein cDNA probe
[24], renal kallikrein mRNA has been localized to the cortical
distal convoluted tubule in the mouse kidney [59, 60], con-
firming both its anatomic localization and its site of synthesis. A
similar pattern has been found in the rat kidney, by the use of
the rat kallikrein cDNA probe [61].
In tubular cells, as in the exocrine glands, kallikrein appears
to be located in the luminal plasma membrane, with its active
site directed into the lumen, enabling it to function as an
ecto-enzyme [62]. Kallikrein in the plasma membrane exists as
both active kallikrein and prokallikrein [33]. By tissue fraction-
ation, Yamada and Erdos [35] have demonstrated high levels of
kallikrein and prokallikrein activity, and of immunoreactivity,
in fractions enriched for apical (luminal) plasma membranes. In
addition, they found that a basolateral membrane enriched
fraction contained active kallikrein and prokallikrein, with
slightly different molecular wt and pH optima, though both
cross—react with kallikrein antibodies [35].
Activation of prokallikrein
Activation of prokallikrein can be induced by trypsin treat-
ment. When kallikrein is assayed in the presence of soybean
trypsin inhibitor, prokallikrein represents 85% of the total
kallikrein present in the rat kidney [63]. Various factors activate
prokallikrein, including detergents, phospholipase A2, lysolec-
ithin and melittin [16, 33, 64]; the physiologic relevance of
activation by such agents, however, is not established. Con-
versely, kallikrein has been reported to be inactivated in vitro
by amiloride, a diuretic which acts on the luminal membrane of
the distal convoluted tubule by blocking sodium channels [65].
Subsequent studies [48], using substrate of two different species
to assay kallikrein activity in vitro, failed to confirm this initial
study of Margolius and Chao [65].
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An as yet uncharacterized inhibitor was identified in early
studies on rat kidney tubules [47]. More recently, local factors
in the tubular lumen such as pH [48], ionic concentration and
the presence of specific cations [40] have been shown to alter
both activity and the extent of partitioning between soluble and
membrane—bound forms.
Physiology
There is considerable uncertainty surrounding the physiolog-
ical regulation of kallikrein production and activation. Various
factors, including sodium balance, prostaglandins, renin, vaso-
pressin, and adrenocortical steroid hormones have been pro-
posed to play roles in these processes. Since kallikrein has been
localized to the lumen of the renal tubule, a primary role for
renal kallikrein outside the kidney is unlikely. Glandular kal-
likrein and prokallikrein have been reported in both rat [66] and
human [67] plasma, suggesting release into the circulation of
tissue kallikrein, a possibility supported by the finding of
kallikrein in the basolateral membrane of tubular cells [35, 56].
However, evidence suggesting that kallikrein is found in the
renal venous effluent comes only from studies with the isolated
perfused kidney [50], and levels in renal lymph are very low [68,
69]. Whether renal kallikrein is released into the circulation,
particularly in a manner that affects renal hemodynamics, is
thus still controversial [4].
While it has not been established that kininogen is the
exclusive substrate for kallikrein activity, kinins are found both
in the tubule and in the urine. The high concentration of
kininase H and other peptidases in the lumen of the proximal
tubule ensures that filtered kinins do not reach the distal tubule
[70]. While filtered kininogen may provide the substrate, low
molecular weight kininogen has been demonstrated in the cells
of both the distal tubule and collecting ducts of the human
kidney [71].
Though most authors agree that kallikrein is involved in
sodium homeostasis, the mechanism is uncertain [2, 4, 72].
Direct infusion of kinins into the renal artery results in in-
creased blood flow, diuresis and natriuresis without changes in
glomerular filtration rate [73], presumably reflecting their potent
vasodilator effect. Given the importance of the intrarenal gen-
eration of kinins [74], it would seem unlikely that kinins infused
into the renal artery exactly mimic the effect of endogenous
products of renal kallikrein activity. Studies using isolated
cortical collecting tubule preparations from both rabbit [75] and
rat [76] suggest a role for kinins in the regulation of the
hydro-osmotic response to vasopressin; in both studies the
response was seen after kinin application to the serosal, but not
to the luminal, surface of the tubule. Administration of a
kininase II inhibitor (angiotensin converting enzyme inhibitor;
Captopril®) results in a natriuresis and diuresis associated with
increased levels of urinary kinins; these effects, however, may
also reflect changes in angiotensin generation. Conversely,
administration of aprotinin [38], or of anti-kinin antibodies, to
saline infused rats results in decreased sodium excretion [77]. In
man there is argument for [78] and against [43] a role for
kallikrein in the acute regulation of sodium homeostasis. It
certainly appears in various models that an acute rise in urine
flow (that is, sodium loading, diuretic administration) results in
increased urinary kallikrein. Further studies have suggested
that this represents a transient effect, and that the ultimate
effect of an acute sodium load is suppression of urinary kal-
likrein [3].
Various studies have suggested that chronic sodium depletion
increases renal and urinary kallikrein [68, 79] while chronic
sodium loading decreases renal and urinary kallikrein [33, 49,
80]. The effect of diuretic therapy appears to be less predictable
[3, 48, 68]. Whether the predominant effects of these manipu-
lations of Na status are on active kallikrein or prokallikrein is
similarly not well established [66].
Kallikrein and the renin—angiotensin system
The roles of the renin—angiotensin system, mineralocorti-
coids and prostaglandins in sodium homeostasis are more
clearly defined; all have several points of interaction with the
kallikrein—kinin system. Several levels of interaction exist be-
tween the renin—angiotensin and kallikrein—kinin systems, in
addition to the postulated effects of mineralocorticoids on renal
kallikrein. One view holds that they represent parallel and
opposing systems, providing both local and systemic circula-
tory control through the vasoconstrictor effects of angiotensin
II and vasodilator effects of bradykinin. Dual modulation is
seen at the level of kininase II [141. Human urinary kallikrein
has been reported to activate plasma pro-renin [10, 11], and rat
urinary kallikrein has been demonstrated to release active renin
from rat renal cortical cells [811. Since the increase in plasma
renin activity seen after a low sodium diet or frusemide was
partially inhibited by aprotinin, it has been suggested that this
decreased activity was a result of inhibition of kallikrein activ-
ity. A recent re-examination of the initial in vitro studies,
however, suggests that the observed increase in renin results
from a kallikrein—mediated decrease in renin degradation in
vitro [821.
In the isolated perfused kidney, both kallikrein and renin
release are simultaneously influenced by changes in perfusion
pressure and renal blood flow, though only renin secretion
alters with beta—adrenergic stimulation or changes in distal
urine composition ISO]. Bonner et al [49], however, found no
relationship between the two systems over a range of chronic
changes in sodium balance.
Mineralocorticoids
A relationship between aldosterone and kallikrein was first
noted in patients with primary aldosteronism, the majority of
whom have high urinary kallikrein levels [83—85], as well as in
cases of secondary aldosteronism such as Bartter's syndrome,
where urinary kallikrein is similarly elevated [86]. In normal
controls low sodium/high potassium diets elevate endogenous
aldosterone, with a concomitant rise in urinary kallikrein activ-
ity [84, 87], with the change in kallikrein levels able to be
blocked by the co-administration of the mineralocorticoid re-
ceptor antagonist, spironolactone [88]. Treatment with the
potent synthetic mineralocorticoid, 9afludrocortisone, similarly
increases urinary kallikrein [84, 87].
Margolius postulated that mineralocorticoids directly regu-
late renal kallikrein 189]. This is supported by the observation
that aldosterone increases, and spironolactone decreases, the
release of kallikrein from rat renal cortical cells in vitro [891.
The steroid concentrations used, however, were markedly
supraphysiological [72].
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In a recent study [88], which used more specific indices of
kallikrein activity and measurements of immunoreactive kal-
likrein in urine, salt restriction predominantly increased active
kallikrein levels in normal controls, with inactive kallikrein
unaltered; this effect was blocked by spironolactone. When
9afludrocortisone was administered, total urinary kallikrein
rose for the first three days to plateau levels. Inactive kallikrein
rose for the first four days and then fell to control levels; urinary
kallikrein activity rose throughout the seven day study. The
changes occurring after three to four days may relate to the
phenomenon of mineralocorticoid escape [90], where natriure-
sis occurs even though the kaliuretic action of the mineralocor-
ticoid is sustained. Most of the studies extend beyond this
period, so that the question then becomes whether the elevated
urinary kallikrein activity plays a role in either sodium retention
[83] or in the natriuresis of escape [72].
Studies on experimental animals have confirmed and ex-
tended these observations. Aldosterone receptors have been
found in the kidney and salivary gland [91, 92], consistent with
a direct role for mineralocorticoids in the control of kallikrein
gene expression. In the rabbit isolated distal convoluted and
cortical collecting tubules, sodium depletion increases both
active and inactive kallikrein; in these sites at least 50% is
inactive, and the ratio remains constant during sodium deple-
tion [36]. As in human studies, chronic salt depletion or
mineralocorticoid treatment in rats increases, and salt loading
decreases, urinary kallikrein and/or renal kallikrein [16, 46, 49,
93—95].
In the rat, the effect of mineralocorticoids is predominantly to
increase urinary levels of active kallikrein [961. Adrenalectomy
decreases both active and inactive urinary kallikrein [49, 94,
96]. Recently, Miller, Chao and Margolius [97] have shown in
the male rat that sodium restriction increases the rate of renal
kallikrein synthesis 1.8-fold, as measured by immunoprecipita-
ble incorporation of [35S]methionine. In an ontogeny study on
fetal lambs, no correlation was seen between plasma aldoster-
one and urinary kallikrein until late in gestation, when they
became highly correlated and remained so postpartum [98].
Despite the close relationship between aldosterone and kal-
likrein, no correlation is observed between aldosterone levels
and plasma or urinary kinin levels [87].
While a large body of evidence favors a direct effect of
aldosterone (mineralocorticoid) on renal kallikrein, the two may
be dissociated. One study showed no change in urinary kal-
likrein after adrenalectomy [99], and another an increase in
renal kallikrein [100]. Both studies used female rats; Chao and
Margolius [100] suggest that the different results reflect a sex
difference in the response of renal kallikrein to adrenalectomy.
Acute administration of aldosterone, with an unambiguous
renal electrolyte response, failed to alter urinary kallikrein
activity [99]. Similarly, in a study of the distribution of kal-
likrein along the rat nephron, sodium restriction, deoxycortico-
sterone treatment and sodium loading failed to induce any
changes [57]. Water immersion, a maneuver which decreases
aldosterone levels, does not change urinary kallikrein levels in
man [43]. Anomalous results are often seen in essential hyper-
tension [101, 1021, and some patients with primary aldosteron-
ism have normal urinary kallikrein levels [85, 101, 103]. In
various animal models of hypertension, deoxycorticosterone
treatment fails to elevate urinary kallikrein [104]. This has been
interpreted as evidence that early hypertensive renal injury may
be reflected in a decrease in urinary kallikrein [103, 104].
If one ignores the situation in hypertension where it would
seem that renal damage may influence the findings, the evidence
of an effect for chronic mineralocorticoid administration upon
renal kallikrein activity is strong. Whether this represents part
of the escape mechanism, or a primary effect of the steroid, is
less clear [49].
Glucocorticoids
The roles of glucocorticoids and/or ACTH are a source of
further confusion in studies of the regulation of renal kallikrein.
Five days of ACTH administration to both hypertensive and
control subjects yields increased urinary kallikrein levels,
which correlate with their DOC but not aldosterone levels [105].
Dexamethasone administration for three days to normal sub-
jects produces an increase in urinary kallikrein activity, unre-
lated to urinary sodium, potassium or aldosterone [106]. In the
rat, ACTH treatment increases aldosterone levels but decreases
kallikrein levels [49]. Similarly, chronic glucocorticoid admin-
istration increases total kallikrein synthesis in the rat [96, 100]
but decreases activation, lowering overall kallikrein activity in
both kidney [49, 96, 100] and urine [49, 93, 107].
Prostaglandins
Prostaglandins are another system with a major vasodilator
role, largely acting in a paracrine mode [108]. Interactions
between kallikrein and prostaglandins are likely also to be in a
local, paracrine context, given the rapid degradation and intra-
renal compartmentalization of both types of signal. Kinins
activate phospholipase A2 which releases arachidonic acid for
the production of POE2 [109]. Since some of the vasodilator and
natriuretic effects of kinins may be attenuated by cyclooxygen-
ase inhibitors [2], it has been argued that prostaglandins may
mediate the effects of kinins [3]. Kinins formed in the distal
nephron may stimulate production of prostaglandins by collect-
ing duct cells (POE2), and medullary and endothelial cells
(prostacyclin). It has also been shown that phospholipase A2
enhances (or activates) membrane—bound kallikrein, perhaps
via the release of lysolecithin [16], and that phospholipase A2
activity is increased in renal membrane preparations after
deoxycorticosterone treatment [96].
Vasopressin
It has been suggested that kallikrein and kinins may modulate
the actions of vasopressin [110]. Though an opposing effect on
vascular tone might be expected, evidence for an interaction in
terms of renal tubular function is less clear. Bradykinin has
been shown to antagonise the effect of vasopressin on short
circuit current in the toad bladder [51], and on the hydro-
osmotic response of the cortical collecting tubule [75]. While
some studies have suggested an effect of vasopressin on urinary
kallikrein activity, levels of urinary and renal kallikrein in male
Brattleboro rats homozygous for hypothalamic diabetes
insipidus are not significantly different from those in their
Long—Evans controls [111]. Though a more recent study [112]
claimed higher renal and urinary kallikrein activity in Brat-
tleboro rats, in any event kallikrein levels show no correlation
with measured vasopressin levels. Kauker et al report, how-
ever, a close correlation between levels of kinin excretion in
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rats and vasopressin excretion [1121. In our laboratory, we find
no difference in renal kallikrein mRNA levels between dildi rats
and LE controls, matched either on an age or weight basis
(Fuller et al, unpublished observations). Though vasopressin is
probably not a determining factor in the control of renal
kallikrein activity, it seems that a complex interaction may well
occur between the two systems.
Atrial natriuretic factor
The recent characterization of atrial natriuretic factor
[113—115] should enable studies of its potential interaction with
the kallikrein—kinin system, particularly as both may be in-
volved, for instance, in the natriuresis of mineralocorticoid
escape [116]. Recently, exogenous glandular kallikrein has been
shown to process atriopeptinogen, the high molecular weight
precursor of atrial natriuretic factor [117]. Similarly, evidence
has been adduced for the participation of kallikrein in the
inactivation of atrial natriuretic peptide(s) [118, 119].
Renal kallikrein pathophysiology
The kallikrein—kinin system has been implicated in certain
pathological conditions, including Bartter's syndrome, hyper-
tension and cystic fibrosis. While urinary kallikrein activity is
increased in Bartter's syndrome, as are plasma renin activity,
aldosterone levels and prostaglandin levels, the elevation in
kallikrein levels is probably secondary to one or more of these
other factors [86]. The primary lesion in Bartter's syndrome
appears to be one of chloride transport in the thick ascending
limb of the loop of Henle [120, 121]; all of the above changes
can be mimicked by chronic frusemide administration [1211.
The role, if any, of the kallikrein—kinin system in hyperten-
sion is a matter of considerable controversy. Since there is
strong evidence that the kidney plays a pivotal role in the
genesis of hypertension [122], intrarenal systems regulating
vascular tone and/or sodium chloride handling may be of
particular importance. In three different models of genetic
hypertension—the Dahi salt—sensitive strain [30], New Zealand
genetically hypertensive rats [123] and Okamoto spontaneously
hypertensive rats [1241—both urinary and tissue kallikrein
levels are reduced during and prior to the development of the
hypertension. Renal kallikrein mRNA levels are indistinguish-
able, however, between genetically hypertensive rats of either
strain, and their appropriate controls (Fuller et al, unpublished
observations). In at least one of these models (Dahl salt—sensi-
tive rats) physicochemical differences in the urinary kallikrein
are observed between hypertensive and control rats, suggesting
strain—specific post—translational differences in processing of
the enzyme [125]. Urinary kallikrein excretion is almost univer-
sally observed to be reduced in renal hypertensive rats of either
the one—kidney or two—kidney type [1].
In 1934 hypertensive patients were first reported to excrete
less kallikrein [126], but it was not until 1971 that this finding
was confirmed [83]. In humans, urinary kallikrein is found to be
lower in black than white children, and lower in summer, late in
the day and in families with essential hypertension [2, 42, 127].
Lower urinary kallikrein levels are seen in children of patients
with essential hypertension; in many patients with hyperten-
sion, however, urinary kallikrein is normal. Predictably, uri-
nary kallikrein is usually increased in hypertension due to
hyperaldosteronism. Early epidemiological studies failed to
take into account many potential variables. Of two recent
studies of patients with essential hypertension, matched with
controls for race, sex, and age, one showed hypertensives to
have lower urinary kallikrein excretion [85], while the other
showed no difference [103]. In established hypertension, de-
creased kallikrein excretion may result from intrarenal damage
[3, 103, 104]. Clearly the epidemiological studies need to be
repeated under similarly stringent conditions before any con-
clusions regarding pathogenesis can be drawn.
A curious observation published recently [128] is that in
diabetics with normal renal function, poor glycemic control is
associated with high urinary kallikrein (enzyme activity and
immunoreactivity), which is reversed with improved control.
Salivary gland kallikrein
Kallikrein was originally identified in exocrine glands on the
basis of its hypotensive effect in vivo and its activity in
non-specific assays of protease activity [129]. The salivary
glands of various species contain several related proteases, with
perhaps the submaxillary gland of the mouse the most outstand-
ing example of this phenomenon. The mouse submaxillary
gland produces, in high abundance, nerve growth factor (NGF)
and epidermal growth factor (EGF) [120], as well as the
acid—peptidase renin and several arginylesteropeptidases in-
cluding EGF—binding protein, NGF y—subunit, J3—NGF—endo-
peptidase, y-renin (a serine protease which mimics the activity
of renin) and kallikrein [25, 261. Unlike renin [131], the
arginylesteropeptidases show only small between—strain differ-
ences [132]. In the rat another homologous protease, tonin, is
synthesized in the submaxillary gland rather than renin [28].
Kallikrein has been localized by immunohistochemistry to
the granular tubules, striated ducts and occasional main duct
cells of the rat submandibular gland [55, 133]. This pattern has
been confirmed in the mouse by the technique of hybridization
histochemistry with the mouse kallikrein cDNA probe [60].
Kallikrein is also found in the sublingual and parotid glands, but
at a much lower abundance, as reviewed by Bhoola, Lemon and
Matthews [129]. In the rat, on the basis of limited sequence
data, pancreatic kallikrein [19] and submaxillary gland kal-
likrein [134] show considerable homology, if not identity.
The precise function of kallikrein in these glands is no better
understood than in the kidney. The luminal distribution sug-
gests an exocrine function, and kallikrein can certainly be
measured in saliva 11351. Other workers have suggested a role
in local regulation of blood flow [129, 136], perhaps counterbal-
ancing the vasoconstrictor role of renin in the mouse, or tonin
in the rat, submaxillary gland. Alternatively, by analogy with
the kidney, kallikrein may regulate the ionic composition of the
exocrine secretion.
Alternative or additional roles are suggested by the finding
that release of kallikrein from these glands is provoked by
sympathetic nerve stimulation [137]. High levels of renin are
found in saliva during aggressive behaviour, so that a large dose
is potentially administered when one mouse bites another [138];
perhaps a similar role exists for kallikrein. In both the mouse
and the rat, submaxillary gland kallikrein levels are regulated by
androgens and thyroxine. The male:female ratio is much higher
(lO:1) in mice than in rats (2:1) [95, 100, 132, l39J, a difference
not seen in the kidney [100]. The rate of kallikrein synthesis in
the rat submaxillary gland, as measured by immunoprecipitable
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incorporation of [35S]methionine, increases 2.3—fold after an-
drogen treatment [97].
Prostatic kallikrein
Kallikrein has also been reported in another androgen—
dependent glandular tissue, the canine prostate [29]. It appears
that the role of kallikrein in the prostate may be an exocrine
one, in that kallikrein has been described in both prostatic fluid
and seminal plasma [29]. Isaacs and Coffey [140] have recently
characterized a species which on enzymatic criteria is a serine
protease, and which accounts for over 90% of the protein in
canine seminal plasma; whether or not this protein is of the
kallikrein family remains to be established. That kallikrein may
play a role in sperm function is supported by the finding of
kallikrein immunofluorescence on the tail and post—acrosomal
regions of canine sperm [140]. Similarly, in uncontrolled trials,
kallikrein treatment has been reported to improve fertility in
oligospermic males [141].
Pancreatic kallikrein
Much of the original work of the characterization of glandular
kallikrein involved porcine pancreatic kallikrein. Its activity
and cellular distribution are very similar to that observed in the
salivary gland. Various studies in different species have local-
ized pancreatic kallikrein to the acinar cells of the exocrine
pancreas [142], and kallikrein activity can be detected in
pancreatic juice [143]. Human pancreatic kallikrein has been
reported to cleave insulin from pro-insulin [144]; recently, by
immunohistochemistry with specific human kallikrein antibod-
ies, kallikrein has also been localized to beta cells in human
pancreatic islets [142]. Unlike the kidney and submaxillary
gland, rat pancreatic immunoreactive kallikrein levels do not
alter with deoxycorticosterone or testosterone treatment [95].
Rat pancreatic kallikrein is one member of a group of simple
serine proteases which are coordinately expressed in the pan-
creas and comprise at least nine members. These include three
isoenzymes of trypsin, three of chymotrypsin, two of elastase
and a single kallikrein [145]. The related genes encoding these
serine proteases evolved from a common ancestral protease
gene through gene duplication events [18, 146]. Genes for the
various serine proteases all reside on different chromosomes,
consistent with an ancient gene duplication event yielding
related but distinct genes [20, 21, 145, 1471. This contrasts with
the kallikrein gene family, which are more closely related, and
presumably more recently duplicated; for kallikrein the various
genes are either contiguous [221 or clustered on a single
chromosome [20]. The coordinate, tissue—specific, expression
of these genes in the pancreas may depend on the presence of
homologous regulatory sequences upstream of the first exon
[21, 145, 147]; such 5' upstream sequences have been demon-
strated to direct tissue—specific gene expression of both the rat
elastase I [148, 149] and chymotrypsin genes [150] in the
exocrine pancreas.
A clinical condition involving the pancreas, respiratory sys-
tem, vas deferens, salivary glands and sweat glands, and in
which glandular kallikrein may be involved, is cystic fibrosis. In
the latter two glands there is a failure of sodium chloride
transport, with high levels of sweat sodium chloride being the
cornerstone of diagnosis. Across other epithelia the problem is
one of increased sodium chloride transport, with development
of hyperviscous secretions.
Several lines of evidence have suggested that the impaired
transport in the sweat glands is due to an inhibitor which blocks
the sodium channels of the luminal membrane, in a manner
analogous to the effect of amiloride, and the reverse of the
situation in hyperaldosteronism where sweat sodium is low
[151]. Other groups have suggested that the predominant defect
is one of relative impermeability of transport epithelia to
chloride ions [152, 153]. Urinary kallikrein excretion in children
with cystic fibrosis is not different from controls, despite the
fact that they generally have secondary hyperaldosteronism
[39], consistent with an abnormality in the kallikrein—kinin
system. On the basis of ultrastructural and enzyme histochem-
ical studies, it has been suggested that the basic defect is due to
a deficiency of the enzyme which cleaves cholecystokinin to
yield the active octapeptide which normally stimulates exocrine
secretion [154].
Abnormalities of amiloride—sensitive sodium transport, of
chloride transport, and of peptide activation in tissues in which
kallikrein may play an important role in precursor processing,
suggest that the condition may result from an abnormality of the
kallikrein—kinin system.
Gut kallikrein
Immunoreactive kallikrein has been demonstrated in the
colonic mucus cells of cat and man [155]. Kallikrein activity has
been reported in rat gastric mucosa [156]. Since other workers
have reported that porcine kallikrein may be absorbed in the rat
gastrointestinal tract [157], and given the lack of demonstrable
kallikrein mRNA in the gut [19], this suggests that the observed
kallikrein might be from submaxillary and pancreatic secre-
tions. However, Miller, Chao and Margolius [97] have reported
incorporation of [35S]methionine into newly synthesized kal-
likrein in the rat colon, as assessed by immunoprecipitable
radioactivity. A role for the kallikrein—kinin system in the
intestine may involve regulation of local blood flow [157] or
chloride ion transport [158].
Since the gastrointestinal tract is a well characterized target
tissue for mineralocorticoids, and since they may modulate the
kallikrein—kinin system, the interactions of these systems may
be significant in gastrointestinal physiology and perhaps
pathophysiology (that is, peptic ulceration).
Pituitary kallikrein
The potential role of kallikrein(s) in post—translational proc-
essing of biologically active peptides makes them candidates for
a role in endocrine physiology in a variety of tissues. The
finding of immunoreactive kallikrein in beta cells of the pancre-
atic islets [142] is one example of such a proposition. In terms
of the pituitary, in vitro studies [28, 159] have suggested that
serine proteases may be implicated in the tissue—specific proc-
essing of pro-opiomelanocortin to its biologically active prod-
ucts.
Powers and Nasjletti [160] found membrane—bound kininoge-
nase activity in the porcine anterior pituitary which on enzy-
matic criteria differed from renal kininogenase, but not neces-
sarily from plasma kallikrein. These same authors demon-
strated kininogenase activity in the pituitary gland of the male
rat, but in this study confined to the neuro-intermediate lobe
960 Fuller and Funder
11611. Subsequently, when female rats were used, kallikrein-
—like activity was identified in the anterior pituitary at a level
eighteenfold that seen in males, though there was no sex
difference for kallikrein activity in the neuro-intermediate lobe
[162], where it appears to be under dopaminergic control [1631.
We have demonstrated the presence of kallikrein mRNA in
the female rat pituitary by Northern blots and hybridization
histochemistry [611. Pituitary mRNA levels also show a marked
sex difference; ablation and replacement studies in both male
and female animals show that expression of the gene is estro-
gen—, and not androgen—dependent [164]. The function of
kallikrein in the pituitary, and its cell type(s) of origin, are not
established. It may be involved in hormone processing, or may
regulate pituitary blood flow. Cell—free translation of total brain
mRNA yields immunoreactive glandular kallikrein [1651; this
preparation, however, did not include the pituitary.
Conclusions
In this review a broad overview has been presented of
glandular kallikrein—its molecular biology, tissue distribution
and potential physiology. The new techniques of recombinant
DNA technology have offered new insights into the character-
ization of kallikrein, or more accurately, the kallikreins. Fur-
ther characterization of their genomic structure and tis-
sue—specific sequence identity should provide insights into the
regulation of their expression. This is of particular interest in
the light of their regulation by androgens in the submaxillary
gland and prostate, regulation by estrogens in the anterior
pituitary, and possible regulation by mineralocorticoids in the
kidney.
Though much of the literature describes a kallikrein—kinin
system, it is by no means clear that the substrate for kallikrein
in any or all of the tissues is kininogen, with the consequent
generation of kinins. Elucidation of the relevant substrate in a
given tissue is of major importance, as it is from a knowledge of
the substrate that the resultant biologically active peptide (and
hence the physiology) may be established. The potential role of
the kallikreins in the pathogenesis of conditions which include
cystic fibrosis, hypertension, peptic ulceration and infertility
provides a further stimulus to the elucidation of their physiol-
ogy and pathophysiology.
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